Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
McKesson
Mallinckrodt
Boehringer Ingelheim
Dow

Last Updated: May 26, 2022

IMPOYZ Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Impoyz patents expire, and what generic alternatives are available?

Impoyz is a drug marketed by Primus Pharms and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-six patent family members in sixteen countries.

The generic ingredient in IMPOYZ is clobetasol propionate. There are fourteen drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the clobetasol propionate profile page.

Paragraph IV (Patent) Challenges for IMPOYZ
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
IMPOYZ Cream clobetasol propionate 0.025% 209483 1 2019-12-06

US Patents and Regulatory Information for IMPOYZ

IMPOYZ is protected by thirteen US patents.

Patents protecting IMPOYZ

Topical formulations comprising a steroid
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF MODERATE PLAQUE PSORIASIS

Topical formulations comprising a steroid
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF PLAQUE PSORIASIS

Topical formulations comprising a steroid
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: PSORIASIS

Topical formulations comprising a steroid
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER

Topical formulations comprising a steroid
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.

Topical formulations comprising a steroid
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER

Topical compositions comprising a corticosteroid
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Topical formulations comprising a steroid
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF MODERATE PLAQUE PSORIASIS

Topical formulations comprising a steroid
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER

Topical formulations comprising a steroid
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: PSORIASIS

Topical formulations comprising a steroid
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.

Topical formulations comprising a steroid
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF PLAQUE PSORIASIS

Topical formulations comprising a steroid
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: PLAQUE PSORIASIS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Primus Pharms IMPOYZ clobetasol propionate CREAM;TOPICAL 209483-001 Nov 28, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Primus Pharms IMPOYZ clobetasol propionate CREAM;TOPICAL 209483-001 Nov 28, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Primus Pharms IMPOYZ clobetasol propionate CREAM;TOPICAL 209483-001 Nov 28, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Primus Pharms IMPOYZ clobetasol propionate CREAM;TOPICAL 209483-001 Nov 28, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for IMPOYZ

See the table below for patents covering IMPOYZ around the world.

Country Patent Number Title Estimated Expiration
Colombia 2017010091 Composiciones tópicas que comprenden un corticosteroide See Plans and Pricing
China 107872972 包含皮质类固醇的外用组合物 (TOPICAL COMPOSITIONS COMPRISING A CORTICOSTEROID) See Plans and Pricing
Australia 2016228574 Topical compositions comprising a corticosteroid See Plans and Pricing
Spain 2861374 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2016145407 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Baxter
McKesson
Merck
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.